Follow the Apexigen, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 25 August 2023 (Retenue fiscale). Among the most active insiders: Sarena Francis Willard. Every trade is free.
26
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Apexigen, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Apexigen, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos de inmuno-oncología. Utiliza su plataforma de descubrimiento de fármacos para crear anticuerpos terapéuticos dirigidos a tumores.